Double maintains 1 strategies that include PTCT - PTC Therapeutics, Inc.
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
RSPA | 44.52% | $293.87M | 0% |
CPRJ | 44.25% | $48.81M | 0.69% |
PBE | 44.01% | $235.57M | 0.58% |
XBI | 43.43% | $5.45B | 0.35% |
PTH | 40.44% | $112.97M | 0.6% |
QQA | 40.33% | $176.36M | 0% |
EFAA | 39.14% | $101.32M | 0% |
CPSJ | 39.12% | $33.06M | 0.69% |
PINK | 38.93% | $142.47M | 0.5% |
IBB | 38.38% | $5.96B | 0.45% |
GNOM | 38.06% | $55.08M | 0.5% |
ARKG | 36.87% | $971.04M | 0.75% |
FBT | 36.80% | $1.09B | 0.56% |
XPH | 35.37% | $166.92M | 0.35% |
IWO | 34.53% | $11.10B | 0.24% |
SECT | 33.84% | $1.87B | 0.78% |
IWC | 33.33% | $830.00M | 0.6% |
TCAF | 33.24% | $3.94B | 0.31% |
BBH | 33.14% | $371.52M | 0.35% |
VBK | 32.88% | $17.73B | 0.07% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
DYN | 38.24% | $1.30B | -59.67% | 0.00% |
NVCR | 37.45% | $2.07B | +20.67% | 0.00% |
VCEL | 33.76% | $2.23B | -14.46% | 0.00% |
COGT | 33.75% | $737.75M | -3.57% | 0.00% |
XNCR | 33.54% | $791.29M | -49.25% | 0.00% |
RCUS | 33.53% | $864.72M | -56.73% | 0.00% |
SUNS | 32.64% | $150.46M | -0.80% | 5.73% |
IDYA | 32.40% | $1.49B | -61.14% | 0.00% |
ACLX | 32.09% | $3.73B | -2.29% | 0.00% |
STOK | 31.02% | $389.90M | -46.59% | 0.00% |
EXPO | 31.02% | $4.18B | -0.56% | 1.40% |
AEIS | 30.75% | $3.58B | -7.04% | 0.43% |
IONS | 30.52% | $4.95B | -28.14% | 0.00% |
CTS | 30.35% | $1.27B | -9.90% | 0.39% |
CNDT | 30.35% | $449.89M | -17.75% | 0.00% |
RXRX | 30.12% | $2.34B | -41.73% | 0.00% |
APGE | 30.10% | $2.36B | -40.23% | 0.00% |
MKSI | 29.95% | $5.50B | -38.65% | 1.10% |
SPSC | 29.72% | $5.04B | -27.80% | 0.00% |
KYMR | 29.67% | $1.92B | -26.32% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BOXX | 0.01% | $5.71B | 0.1949% |
FLRN | 0.09% | $2.80B | 0.15% |
PWZ | -0.09% | $694.97M | 0.28% |
CHIQ | -0.16% | $260.60M | 0.65% |
SLV | -0.21% | $15.29B | 0.5% |
GCC | 0.22% | $148.77M | 0.55% |
SOYB | 0.23% | $25.67M | 0.22% |
FLMI | 0.27% | $606.25M | 0.3% |
SIVR | -0.29% | $1.63B | 0.3% |
IBMR | -0.31% | $219.07M | 0.18% |
FMF | -0.33% | $154.62M | 0.95% |
IXC | -0.45% | $1.81B | 0.41% |
CXSE | -0.57% | $433.82M | 0.32% |
BCD | -0.59% | $248.86M | 0.3% |
USDU | -0.60% | $213.62M | 0.5% |
ULST | -0.69% | $586.48M | 0.2% |
XONE | 0.70% | $627.32M | 0.03% |
TBLL | -0.79% | $2.07B | 0.08% |
GBIL | 0.81% | $6.30B | 0.12% |
IBTG | 0.89% | $1.82B | 0.07% |
Yahoo
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on March 24, 2025, the company approved non-statutory stock options to purchase an aggregate of 12,000 shares of its common stock and 28,220 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 35 new employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires' employment compensation.
Yahoo
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the European Commission (EC) has adopted the opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) to not renew the authorization of Translarna™ (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy. While this action effectively removes the drug's conditional marketing authorization in the European Economic Area, the EC indicated that individual countries with
Finnhub
PTC Therapeutics said onFriday its inherited progressive muscle-wasting disorder drugwill no longer be available for sale in the EU as the EuropeanCommission has decided not to renew its...
Finnhub
PTC Therapeutics said onFriday the European Commission will remove its inheritedprogressive muscle-wasting disorder from the region after anadvisory panel reaffirmed a negative opinion of the drug...
Finnhub
PTC Therapeutics Inc: * PTC THERAPEUTICS PROVIDES REGULATORY UPDATE ON TRANSLARNA™ IN EUROPE * PTC THERAPEUTICS : DISAPPOINTED THAT AFTER PROLONGEDPERIOD OFREVIEW...
Yahoo
PTC Therapeutics, Inc. (NASDAQ: PTCT) today shared new data being presented from the Phase 3 APHENITY trial and subsequent open-label extension study at the 2025 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting. These data provide further evidence of the potential meaningful benefits of sepiapterin treatment for the full spectrum of phenylketonuria (PKU) patients, including significant diet liberalization.
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
DDS | 0.02% | $5.71B | -19.48% | 0.21% |
CINF | 0.03% | $22.79B | +17.22% | 2.26% |
STNG | 0.09% | $1.91B | -46.50% | 4.27% |
FIGS | -0.10% | $763.85M | -5.62% | 0.00% |
COP | -0.11% | $130.12B | -19.57% | 3.05% |
SO | 0.11% | $99.95B | +27.03% | 3.14% |
AGO | -0.11% | $4.35B | -0.02% | 1.47% |
EOG | 0.13% | $70.12B | -0.98% | 2.92% |
LX | 0.14% | $1.43B | +517.22% | 1.32% |
STZ | -0.14% | $33.20B | -32.39% | 2.23% |
XOS | 0.15% | $27.62M | -66.41% | 0.00% |
WPC | 0.16% | $13.72B | +11.09% | 4.20% |
WBA | -0.16% | $9.68B | -48.41% | 6.71% |
GORV | 0.18% | $51.52M | -88.36% | 0.00% |
OMCL | -0.18% | $1.64B | +19.77% | 0.00% |
INSW | -0.18% | $1.63B | -30.84% | 1.48% |
SITC | -0.20% | $662.20M | +10.50% | 1.04% |
PFLT | -0.22% | - | - | 10.99% |
DV | 0.31% | $2.21B | -62.06% | 0.00% |
NNVC | 0.32% | $18.93M | +4.31% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VIXY | -23.87% | $195.31M | 0.85% |
BTAL | -22.91% | $393.05M | 1.43% |
TAIL | -18.15% | $84.36M | 0.59% |
BNO | -12.73% | $96.15M | 1% |
USO | -11.79% | $947.20M | 0.6% |
TPMN | -11.73% | $33.38M | 0.65% |
USCI | -11.71% | $232.14M | 1.07% |
USL | -11.62% | $47.09M | 0.85% |
DBE | -11.37% | $54.74M | 0.77% |
DBO | -11.32% | $199.76M | 0.77% |
OILK | -9.76% | $67.10M | 0.69% |
COMT | -9.34% | $671.98M | 0.48% |
KMLM | -9.21% | $222.39M | 0.9% |
CNYA | -8.65% | $221.36M | 0.6% |
ASHR | -8.12% | $2.66B | 0.65% |
GSG | -7.65% | $1.04B | 0.75% |
DBA | -7.36% | $823.19M | 0.93% |
CTA | -7.03% | $943.11M | 0.76% |
UGA | -6.96% | $88.53M | 0.97% |
SGOV | -6.96% | $39.32B | 0.09% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CME | -12.12% | $94.50B | +21.80% | 3.99% |
SHEL | -11.57% | $218.15B | +8.49% | 3.84% |
CBOE | -11.41% | $23.32B | +21.20% | 1.08% |
TTE | -11.39% | $134.58B | -6.80% | 5.27% |
FINV | -10.40% | $1.43B | +93.65% | 2.46% |
NEUE | -10.16% | $59.29M | +5.38% | 0.00% |
LU | -9.48% | $2.48B | -29.86% | 0.00% |
BNED | -9.14% | $343.94M | -86.05% | 0.00% |
HUSA | -8.77% | $11.30M | -45.84% | 0.00% |
DB | -8.64% | $45.49B | +51.93% | 2.09% |
PSEC | -8.61% | - | - | 15.91% |
PRPO | -8.60% | $9.29M | -6.42% | 0.00% |
E | -8.57% | $47.11B | -2.40% | 6.85% |
YRD | -8.04% | $636.81M | +61.64% | 2.85% |
GCT | -7.44% | $596.20M | -43.45% | 0.00% |
OIS | -7.36% | $323.11M | -15.42% | 0.00% |
EH | -6.83% | $913.88M | +0.88% | 0.00% |
K | -6.76% | $28.47B | +43.95% | 2.75% |
EQNR | -6.62% | $71.18B | +1.70% | 5.36% |
BP | -6.27% | $89.30B | -10.14% | 5.58% |
Current Value
$52.891 Year Return
Current Value
$52.891 Year Return